A recent independent publication cites using HemaCare leukopaks for their evaluation of a CAR T cell therapy’s antitumor potency.
As the CAR T cell therapy field continues to grow, developers seek to refine techniques that will improve both the safety and efficacy of this promising cancer immunotherapy strategy. Scientists at Juno Therapeutics (Celgene) have been working to improve the potency of a CD19-targeted CAR T therapeutic currently in phase 1 and 2 clinical trials.